Innovative Technology Singulex’s proprietary Single Molecule Counting technology offers ultra-sensitive immunodiagnostics, enabling the detection of biomarkers at unprecedented levels. This unique positioning suggests potential sales opportunities with laboratories and healthcare providers seeking highly accurate diagnostic solutions.

Expansion & Development The company is actively developing additional assays for infectious and inflammatory diseases and exploring point-of-care platforms, presenting opportunities to introduce new products to healthcare institutions, clinics, and diagnostic centers looking for advanced, rapid testing options.

Strategic Collaborations Partnerships with organizations like QIAGEN and the University of Manchester highlight Singulex’s focus on co-developing companion diagnostics and expanding its technological reach, which could open avenues for joint sales efforts and collaborative market entry strategies with biotech and pharma partners.

Regulatory Milestones With the Clarity system receiving CE marking and a 510(k) submission for FDA clearance, Singulex is positioned for broader commercial deployment in both Europe and the US, offering sales teams opportunities to target hospital systems, diagnostic labs, and health networks seeking validated, high-sensitivity diagnostics.

Market Position & Funding Having secured $50 million in funding and operating within a competitive biotech landscape alongside companies like Quanterix and Bio-Techne, Singulex is poised for growth, making it a promising target for investors and distributors aiming to capitalize on innovative diagnostic technologies in the biotech sector.